Difference between revisions of "Part:BBa K3846177"
Crisprcaspr (Talk | contribs) |
|||
| Line 3: | Line 3: | ||
<partinfo>BBa_K3846177 short</partinfo> | <partinfo>BBa_K3846177 short</partinfo> | ||
| − | + | Our project focuses on enzymatic reactions catalysed by cytochrome P450 enzymes. This group of enzymes always rely on a reductase to be functional. To increase the activity of the P450 enzyme we decided to create fusion proteins, consisting of an N-terminal cytochrome P450 enzyme and a C-terminal NADPH-cytochrome P450 reductase connected by a linker sequence. It is likely that the composition of the linker sequence influences the activity of the fusion protein since electrons have to be transferred from the reductase to the P450 enzyme and the structural arrangement of the domains should have an effect on this process. Optimising the linker sequence is therefore crucial for reaching optimal enzyme activity. | |
| + | To allow modular combinations of different P450 enzymes, reductases and linkers we designed these parts interchangeably using the following MoClo compatible fusion sites. | ||
| + | |||
| + | <b>fusion sites: </b> | ||
| + | * CYP P450 enzyme (AATG -TTCG) | ||
| + | * linker sequence (TTCG - ATCG) | ||
| + | * reductase (ATCG - GCTT) | ||
| + | |||
| + | This trimmed <b><u>protein sequence</u></b> was created with a bioinformatic software tool for a systematic analysis of the effect of linker length and composition on CYP1A1-CPR fusion protein activity. Cytochrome P450 enzymes and reductases needed to be trimmed at the C-terminus or the N-terminus respectively to allow integration of the calculated optimal linker sequence. It was planned to use protein activity assay to confirm the validity of the results calculated with the software tool. | ||
| + | [https://2021.igem.org/Team:Hambur/Model][https://2021.igem.org/Team:Hamburg/Software] | ||
| + | |||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
| Line 17: | Line 27: | ||
<partinfo>BBa_K3846177 parameters</partinfo> | <partinfo>BBa_K3846177 parameters</partinfo> | ||
<!-- --> | <!-- --> | ||
| + | |||
| + | |||
| + | ===iGEM Hamburg 2021 part collection=== | ||
| + | Terpenoids are an important group of natural products used as biofuels, drugs or fragrances. Naturally occuring in plants it has been shown that microbial terpene production in microorganisms like yeast, E. coli or cyanobacteria is possible. | ||
| + | Nevertheless iGEM projects seem to rarely focus on this interesting class of natural products which is correlated with a lack of useful parts inside the iGEM registry. | ||
| + | |||
| + | Fortunately we were able to change that and designed a novel golden gate based toolbox which allows. | ||
| + | <ol style="list-style-type:lower-alpha"> | ||
| + | <li>production of terpenoid precursors and simple terpenoids</li> | ||
| + | <li>creation of CYP P450-reductase fusion enzymes to optimise processing of terpenoid precursors and production of bioactive target products</li> | ||
| + | <li>modularity of the system to enable exchange of linker sequences/promoters/etc. (MoClo-compatible toolbox)</li> | ||
| + | </ol> | ||
| + | |||
| + | ===MoClo-based Part Design 2.0=== | ||
| + | <p>To improve the usefulness of our parts, we then aimed to make our parts compatible with the MoClo standard of goten gate based IIS restriction enzyme assembly. Thereby we expanded the Common Genetic Syntax for fusion sites to allow the creation of a) fusion proteins connected by linker sequences and b) multiple CDS expressed in an operon. | ||
| + | More useful information and an overview of all our parts can be found on our [https://2021.igem.org/Team:Hamburg/Part_Collection wiki]. | ||
| + | |||
| + | [[File:T--Hamburg--parts overview MolClo.png|600px|thumb|left|'''Figure 1''': <b> MoClo syntax of the part collection. </b> <br>]] | ||
Latest revision as of 02:47, 20 October 2021
RAT CPR shortened sequence for linker tests (1)
Our project focuses on enzymatic reactions catalysed by cytochrome P450 enzymes. This group of enzymes always rely on a reductase to be functional. To increase the activity of the P450 enzyme we decided to create fusion proteins, consisting of an N-terminal cytochrome P450 enzyme and a C-terminal NADPH-cytochrome P450 reductase connected by a linker sequence. It is likely that the composition of the linker sequence influences the activity of the fusion protein since electrons have to be transferred from the reductase to the P450 enzyme and the structural arrangement of the domains should have an effect on this process. Optimising the linker sequence is therefore crucial for reaching optimal enzyme activity. To allow modular combinations of different P450 enzymes, reductases and linkers we designed these parts interchangeably using the following MoClo compatible fusion sites.
fusion sites:
- CYP P450 enzyme (AATG -TTCG)
- linker sequence (TTCG - ATCG)
- reductase (ATCG - GCTT)
This trimmed protein sequence was created with a bioinformatic software tool for a systematic analysis of the effect of linker length and composition on CYP1A1-CPR fusion protein activity. Cytochrome P450 enzymes and reductases needed to be trimmed at the C-terminus or the N-terminus respectively to allow integration of the calculated optimal linker sequence. It was planned to use protein activity assay to confirm the validity of the results calculated with the software tool. [1][2]
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
iGEM Hamburg 2021 part collection
Terpenoids are an important group of natural products used as biofuels, drugs or fragrances. Naturally occuring in plants it has been shown that microbial terpene production in microorganisms like yeast, E. coli or cyanobacteria is possible. Nevertheless iGEM projects seem to rarely focus on this interesting class of natural products which is correlated with a lack of useful parts inside the iGEM registry.
Fortunately we were able to change that and designed a novel golden gate based toolbox which allows.
- production of terpenoid precursors and simple terpenoids
- creation of CYP P450-reductase fusion enzymes to optimise processing of terpenoid precursors and production of bioactive target products
- modularity of the system to enable exchange of linker sequences/promoters/etc. (MoClo-compatible toolbox)
MoClo-based Part Design 2.0
To improve the usefulness of our parts, we then aimed to make our parts compatible with the MoClo standard of goten gate based IIS restriction enzyme assembly. Thereby we expanded the Common Genetic Syntax for fusion sites to allow the creation of a) fusion proteins connected by linker sequences and b) multiple CDS expressed in an operon. More useful information and an overview of all our parts can be found on our wiki.
